Login to Your Account

Market Uptake Still Challenging

CHMP Backs First Biosimilar MAb from Hospira, Celltrion

By Jennifer Boggs
Managing Editor

Monday, July 1, 2013
Almost exactly a year after Remsima (infliximab) won approval in Korea as the first ever biosimilar monoclonal antibody (MAb), the Remicade copycat drug won a positive opinion from Europe's Committee for Medicinal Products for Human Use (CHMP), clearing the way for formal European approval within the next three months.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription